JP2017523959A - ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 - Google Patents

ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Download PDF

Info

Publication number
JP2017523959A
JP2017523959A JP2016575360A JP2016575360A JP2017523959A JP 2017523959 A JP2017523959 A JP 2017523959A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2016575360 A JP2016575360 A JP 2016575360A JP 2017523959 A JP2017523959 A JP 2017523959A
Authority
JP
Japan
Prior art keywords
absent
lys
ala
arg
cys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016575360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523959A5 (enExample
Inventor
グレゴリー トーマス ボーン，
グレゴリー トーマス ボーン，
マーク レスリー スマイス，
マーク レスリー スマイス，
ブライアン トロイ フレデリック，
ブライアン トロイ フレデリック，
シモネ ビンク，
シモネ ビンク，
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド, プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2017523959A publication Critical patent/JP2017523959A/ja
Publication of JP2017523959A5 publication Critical patent/JP2017523959A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2016575360A 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 Withdrawn JP2017523959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018382P 2014-06-27 2014-06-27
US62/018,382 2014-06-27
PCT/US2015/038370 WO2015200916A2 (en) 2014-06-27 2015-06-29 Hepcidin and mini-hepcidin analogues and uses therof

Publications (2)

Publication Number Publication Date
JP2017523959A true JP2017523959A (ja) 2017-08-24
JP2017523959A5 JP2017523959A5 (enExample) 2019-02-28

Family

ID=54938965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575360A Withdrawn JP2017523959A (ja) 2014-06-27 2015-06-29 ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用

Country Status (10)

Country Link
US (2) US20170313754A1 (enExample)
EP (1) EP3161164A4 (enExample)
JP (1) JP2017523959A (enExample)
KR (1) KR20170043509A (enExample)
CN (1) CN107075574A (enExample)
AU (1) AU2015279571A1 (enExample)
CA (1) CA2953721A1 (enExample)
IL (1) IL249692A0 (enExample)
SG (1) SG11201610799WA (enExample)
WO (1) WO2015200916A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
JP2024513392A (ja) * 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2186524B1 (en) 2001-05-25 2018-02-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
WO2019018377A1 (en) * 2017-07-18 2019-01-24 Arizona Board Of Regents On Behalf Of The University Of Arizona DISULFIDE-MASKED PRO-CHELATE COMPOSITIONS AND METHODS OF USE
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
JP2017535527A (ja) 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3399996A4 (en) * 2016-01-08 2019-10-16 La Jolla Pharmaceutical Company METHOD FOR THE ADMINISTRATION OF HEPCIDINE
CA3017926C (en) 2016-03-23 2023-10-10 Protagonist Therapeutics, Inc. Methods for synthesizing .alpha.4.beta.7 peptide antagonists
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
AU2017324446A1 (en) * 2016-09-06 2019-03-28 La Jolla Pharmceutical Company Methods of treating iron overload
CA3047320A1 (en) * 2016-12-19 2018-06-28 La Jolla Pharmaceutical Company Methods of administering hepcidin
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019157268A1 (en) * 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso
CA3139209A1 (en) 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20220372099A1 (en) 2019-09-03 2022-11-24 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3156007A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US20220372136A1 (en) * 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating anemia of chronic disease
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
CA3181577A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
CA3181583A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
US11746100B2 (en) 2020-04-28 2023-09-05 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CN111560051B (zh) * 2020-05-26 2022-11-25 大连工业大学 一种具有促铁吸收活性的虾源九肽及其应用
CN114252627A (zh) * 2020-09-24 2022-03-29 首都医科大学附属北京世纪坛医院 尿液铁调素及其多肽片段在过敏性疾病中的应用
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
CN115703826B (zh) * 2021-08-03 2025-05-06 浙江大学 铁调素改造体及其应用
EP4536683A4 (en) * 2022-06-07 2026-06-10 Protagonist Therapeutics Inc HEPCIDINE MIMETIC AGENTS FOR THE TREATMENT OF SICKLE CELL DISEASE
US20260224514A1 (en) * 2022-09-15 2026-08-06 Migal Galilee Research Institute Ltd. Site-specific activation of regulatory t cells
WO2025224128A1 (en) 2024-04-24 2025-10-30 Institut National de la Santé et de la Recherche Médicale Methods of treatment of iron overload associated diseases by administration hepcidin locally in the gut

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130588A1 (es) * 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
CN101358201A (zh) * 2007-07-31 2009-02-04 钱忠明 重组人铁调素腺病毒、其制备方法及应用
CN101307085B (zh) * 2007-08-01 2012-06-13 香港理工大学深圳研究院 抑制铁调素调节蛋白的siRNA、重组慢病毒及其应用
GR1006896B (el) * 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, Μεθοδος παραγωγης μιας πεπτιδικης ορμονης
WO2010065815A2 (en) * 2008-12-05 2010-06-10 The Regents Of The University Of California Mini-hepcidin peptides and methods of using thereof
US20130236977A1 (en) * 2010-05-24 2013-09-12 Children's Medical Center Corporation Compositions and methods for plasma peptide analysis
BR112014013697A2 (pt) * 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
EP4091624A1 (en) * 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023532728A (ja) * 2020-07-02 2023-07-31 タンペレ・ユニバーシティー・ファウンデーション・エスアール レニンに基づくヘプシジン分析法
JP2023536463A (ja) * 2020-07-28 2023-08-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
JP7871246B2 (ja) 2020-07-28 2026-06-08 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲート型ヘプシジン模倣体
JP2024513392A (ja) * 2021-04-01 2024-03-25 プロタゴニスト セラピューティクス， インコーポレイテッド コンジュゲートされたヘプシジン模倣物

Also Published As

Publication number Publication date
SG11201610799WA (en) 2017-01-27
US20200017566A1 (en) 2020-01-16
IL249692A0 (en) 2017-02-28
CA2953721A1 (en) 2015-12-30
WO2015200916A2 (en) 2015-12-30
EP3161164A2 (en) 2017-05-03
EP3161164A4 (en) 2018-04-25
US20170313754A1 (en) 2017-11-02
AU2015279571A1 (en) 2017-02-02
KR20170043509A (ko) 2017-04-21
CN107075574A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
US12269856B2 (en) Hepcidin analogues and uses thereof
US20200017566A1 (en) Hepcidin and mini-hepcidin analogues and uses therof
US11472842B2 (en) Analogues of hepcidin mimetics with improved in vivo half lives
EP3570864B1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20200361992A1 (en) Conjugated hepcidin mimetics
JP2023540679A (ja) コンジュゲートされたヘプシジン模倣物
JP2024513392A (ja) コンジュゲートされたヘプシジン模倣物
WO2022212698A1 (en) Conjugated hepcidin mimetics
WO2025226506A1 (en) Mono- and dual-agonist compounds of human glp1r and gipr for obesity & t2dm
WO2026060110A1 (en) Dual- and tri-agonist compounds for obesity & t2dm
CN116457000A (zh) 缀合的铁调素模拟物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190115

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190328